Neos Therapeutics, Inc. (NEOS)

[BioSpecialist]

NEOS (MC $91 M) $60 M Cash 1 Drug approved /2 Drugs close to FDA approval targeting Billion Dollar Markets .

Very attractive and unknown FDA play with HUGE upside Potential i see thefair value around $20 per share .GL

NEOS Therapeutics (NEOS)

Market Cap: $91 M
Cash: $60 M
Price $5.90

Shares Out: 16.06 M

Presentation
http://investors.neostx.com/phoenix.zhtml?c=254075&p=irol-presentations

•Adzenys XR-ODT launched May, 2016
•Robust prescription growth since launch
•22,797 total TRx through December 2, 2016

•Pipeline includes two late-stage product candidates for the treatment of ADHD

•Amphetamine XR-Oral Suspension —NDA Submitted Nov 15, 2016

•Cotempla (methylphenidate) XR-ODT —NDA resubmitted Dec 20, 2016